725MO Phase I trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3-positive (+) tumours: Focus on neuroendocrine carcinomas
Gambardella, V., Castillon, J. Capdevila, Kuboki, Y., Alese, O., Morgensztern, D., Sayehli, C.M., Sanmamed, M.F., Arriola, E., Hamed, Z. Oum', Song, E., Studeny, M., Wermke, M.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
75MO Phase I trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3+ tumors: Focus on Asian pts
Kuboki, Y., Gambardella, V., Capdevila Castillon, J., Alese, O.B., Morgensztern, D., Sayehli, C.M., Sanmamed, M.F., Arriola, E., Wolf, J., Owonikoko, T.K., Studeny, M., Bouzaggou, M., Song, E., Wermke, M.
Published in Annals of oncology (01.11.2023)
Published in Annals of oncology (01.11.2023)
Get full text
Journal Article
729MO Final results of the first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in combination with nivolumab in subjects with solid tumors relapsed/refractory to prior anti-PD1/PD-L1 treatment
Melero, I., De Miguel, M.J., Alonso Casal, G., Goebeler, M-E., Ramelyte, E., Calvo, E., Garralda, E., Dummer, R., Rodríguez-Ruiz, M.E., Sayehli, C.M., Sanmamed, M.F., Ramón, J.L., Lostes Bardaji, M.J., Gromke, T., Schuler, M.H.H., Fettes, P., Klar, K., Schuberth-Wagner, C., Wischhusen, J., Leo, E.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
Phase I experience with rogaratinib in patients with head and neck cancer selected based on FGFR mRNA overexpression
Joerger, M., Takahashi, S., Sayehli, C.M., Slosarczyk, S., Navarro Mendivil, A., Cassier, P.A., Nogai, H., Zhang, C., Sei, F., Bender, S., Ellinghaus, P., Tahara, M.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Anti-tumor activity of the pan-FGFR inhibitor rogaratinib in patients with advanced urothelial carcinomas selected based on tumor FGFR mRNA expression levels
Schuler, M., Nogova, L., Heidenreich, A., Tai, D., Cassier, P., Richly, H., Cho, B.C., Sayehli, C.M., Navarro, A., Bender, S., Ocker, M., Nogai, H., Wagner, A., Ince, S., Ellinghaus, P., Joerger, M.
Published in Annals of oncology (01.09.2017)
Published in Annals of oncology (01.09.2017)
Get full text
Journal Article
A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors: Results from rogaratinib Phase-1 study
Joerger, M., Soo, R.A., Cho, B.C., Navarro, A., Sayehli, C.M., Richly, H., Tai, D., Kim, D-W., Wolf, J., Cassier, P., Bender, S., Ellinghaus, P., Ince, S., Rajagopalan, P., Ocker, M., Schuler, M.
Published in Annals of oncology (01.09.2017)
Published in Annals of oncology (01.09.2017)
Get full text
Journal Article
118O Definitive results for NSCLC and bladder cancer cohorts in the phase IIa trial of visugromab (CTL-002) in advanced/metastatic anti-PD/PD-L1 relapsed/refractory solid tumors (GDFATHER-trial)
Melero, I., De Miguel, M.J., Casal, G. Alonso, De Velasco Oria, G.A., Ramelyte, E., Joerger, M., Martin-Liberal, J., König, D., Sayehli, C.M., Gromke, T., RodrÍguez-Ruiz, M.E., Calvo, E., Garralda, E., Soto-Castillo, J.J., Dummer, R., Villarrubia, J. Esteban, Goebeler, M-E., Fettes, P., Klar, K., Leo, E.
Published in Immuno-oncology technology (01.12.2023)
Published in Immuno-oncology technology (01.12.2023)
Get full text
Journal Article